Pacific Biosciences of California 과거 수익 실적

과거 기준 확인 0/6

Pacific Biosciences of California의 수입은 연평균 -40.2%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 13.9%의 비율로 증가했습니다. 매출은 연평균 18.7%의 비율로 증가해 왔습니다.

주요 정보

-40.2%

수익 성장률

-30.8%

EPS 성장률

Life Sciences 산업 성장	26.8%
매출 성장률	18.7%
자기자본 수익률	-87.0%
순이익	-227.7%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Pacific Biosciences of California 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:P09 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	173	-394	165	146
30 Jun 24	189	-400	172	168
31 Mar 24	200	-297	174	182
31 Dec 23	201	-307	170	187
30 Sep 23	170	-309	169	185
30 Jun 23	146	-319	162	185
31 Mar 23	134	-321	161	189
31 Dec 22	128	-314	161	193
30 Sep 22	137	-299	153	193
30 Jun 22	140	-206	148	173
31 Mar 22	135	-175	138	145
31 Dec 21	131	-181	124	113
30 Sep 21	122	-37	105	88
30 Jun 21	106	-77	94	77
31 Mar 21	92	-59	80	69
31 Dec 20	79	29	73	64
30 Sep 20	80	-46	84	61
30 Jun 20	83	-51	71	59
31 Mar 20	90	-53	75	59
31 Dec 19	91	-84	75	60
30 Sep 19	82	-115	62	62
30 Jun 19	79	-111	68	61
31 Mar 19	76	-109	64	62
31 Dec 18	79	-103	63	63
30 Sep 18	84	-93	58	62
30 Jun 18	89	-90	58	63
31 Mar 18	88	-93	59	65
31 Dec 17	93	-92	59	65
30 Sep 17	94	-90	58	66
30 Jun 17	96	-86	56	68
31 Mar 17	97	-79	51	68
31 Dec 16	91	-74	48	68
30 Sep 16	101	-57	48	66
30 Jun 16	90	-37	46	65
31 Mar 16	94	-31	46	62
31 Dec 15	93	-32	45	60
30 Sep 15	73	-49	42	58
30 Jun 15	80	-60	41	54
31 Mar 15	67	-67	40	51
31 Dec 14	61	-66	38	48
30 Sep 14	53	-64	37	47
30 Jun 14	40	-76	38	46
31 Mar 14	34	-77	38	45
31 Dec 13	28	-79	39	45

양질의 수익: P09 은(는) 현재 수익성이 없습니다.

이익 마진 증가: P09 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: P09 은(는) 수익성이 없으며 지난 5년 동안 연간 40.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 P09 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: P09 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( 5.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: P09 현재 수익성이 없기 때문에 마이너스 자본 수익률( -87.01% )을 갖습니다.

Pacific Biosciences of California 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors